‘Global Influenza Vaccines – World Industry Market Outlook And Forecasts 2018-2028’

26 July 2018
Pharma

Visiongain’s new 138-page report Global Influenza Vaccines Market Outlook 2018-2028: Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments For Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other indicates that the influenza vaccines market will generate revenues of $3.53bn in 2018.

The study analyses events, prospects and sales opportunities shaping the development, production and marketing of influenza vaccines. That investigation shows multilevel revenue forecasting and qualitative assessments. The work also explores activities of companies providing these vaccines, assessing their potentials from 2018 onwards. This vaccines market holds many commercial opportunities from 2018, including rising sales in developed and emerging countries.

Visiongain predicts that the influenza vaccines market will continue to grow at a steady pace through2018-2028. This growth is mainly driven by the ageing population globally and the increasing prevalence of chronic illness. Adding to this will be the growing demand from emerging markets as their economies prosper, their healthcare expenditures also rise.
The study shows how the market share for the various countries change due to political and economic structural changes, and also the emergence of new industry players. Further, the shifts in market share of the submarkets are also shown, shedding light on the future developments in the influenza vaccine technology. The study also includes the next major breakthrough that will transform the industry; the much awaited Universal Flu vaccine, which will provide immunity against all types of influenza viruses. A company that is currently developing this vaccine has also been interviewed in the report.

The pharmaceutical industry analyst at visiongain for this report said: “Prevalence of influenza rises globally. The most effective way to combat that widespread infection is through vaccination. As the world moves towards an ageing population, people’s susceptibility to influenza increases, raising demand for flu vaccines. Also improving healthcare systems, growing flu awareness and high birth rates in developing countries will fuel demand for existing and new influenza vaccines from 2018. The influenza vaccination industry thus holds great potential for progress and high sales. Vaccination is a stressful event, especially for children, and the company that can provide a uniquely non-stress vaccination will reap high rewards.

The influenza virus changes each year and new vaccines are required to maintain immunization against the infection. With this in mind, the influenza vaccine market can be assured of high demand. And the development of a universal influenza vaccine that provides protection against seasonal and pandemic strains of the virus could potentially transform the industry.”

Global Influenza Vaccines Market Outlook 2018-2028: Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments For Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostics and outsourced services, including contract research (CROs), manufacturing (CMOs) and selling (CSOs).

Notes for Editors
If you are interested in a more detailed overview of this yearbook, please send an e-mail to sara.peerun@visiongain.com or call on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the energy, telecoms, pharmaceutical, defence and materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

Read

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

Read

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

Read

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031

Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.

01 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever